Nasdaq:PPCB
Propanc Biopharma, Inc.
A pre-revenue biopharma firm with a robust pipeline of oncology-focused therapeutic candidates supported by substantial paid-in capital.
Key Metrics
Investment Thesis
Bull Case
Investors may buy PPCB for early exposure to a potential blockbuster oncology drug before it hits the market, capitalizing on the asymmetric risk-reward profile common in biotech investing. The company's substantial paid-in capital of $138.2M and manageable total liabilities of $5.7M suggest sufficient runway to advance multiple candidates through costly Phase II or III trials without immediate dilution. A successful clinical milestone could trigger a massive re-rating of the stock price as it transitions from a speculative asset to one with commercial value.
Bear Case
The company faces severe financial distress indicators, including a retained earnings deficit of -$125.6M and a massive non-cash loss in 2025 that obscures true cash burn rates. With zero revenue and total assets barely exceeding liabilities when excluding equity, the business model is entirely dependent on continuous external capital injections which may become scarce if market sentiment shifts. The lack of current assets relative to long-term R&D commitments creates liquidity pressure that could force a distressed sale or dilutive financing round.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (PPCB) is a biopharmaceutical company focused on the discovery and development of novel therapeutics, primarily targeting oncology and other serious diseases. The company operates in the competitive pharmaceutical market, leveraging internal research pipelines and strategic partnerships to advance its clinical candidates toward regulatory approval. Despite currently lacking commercial revenue, the firm maintains significant cash reserves from financing activities to fuel its R&D initiatives.
Analysis
Management Discussion
The company reported a significant net loss of $58.9M in 2025, driven largely by non-cash adjustments and operating expenses related to R&D and administration, while cash flow from operations turned negative at -$405k. However, the firm successfully secured $490k in financing cash flow, resulting in a net cash position that remains positive despite the reduction in beginning cash reserves. Management appears to be prioritizing pipeline progression over immediate profitability, utilizing share-based compensation of $4.6M to align employee incentives with long-term value creation.
Industry Overview
The biopharmaceutical industry is characterized by high barriers to entry, lengthy development cycles, and significant regulatory hurdles, where only a small fraction of compounds reach market approval. Companies like PPCB operate in an environment where innovation drives value but failure rates are extremely high, requiring substantial capital reserves to sustain operations until commercialization. Market dynamics heavily favor firms with differentiated mechanisms of action that can address unmet medical needs in oncology and other therapeutic areas.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $1.8M | $1.5M | $57.3M |
| Operating Income | $-1.8M | $-1.5M | $-57.3M |
| R&D | $247.9K | $248.1K | $223.7K |
| G&A | $1.5M | $1.3M | $57.0M |
| Stock-Based Comp | $2.4K | — | $4.6M |
| Depreciation | $1.7K | $297 | — |
| Other OpEx | $28.8K | $34.1K | $26.6K |
| Non-Operating Income | $-1.0M | $-413.6K | $-1.6M |
| Interest Expense | $532.8K | — | — |
| Interest Income | $36 | $60 | $9 |
| Pre-Tax Income | $-2.8M | $-1.9M | $-58.9M |
| Income Tax | $-129.8K | $-129.1K | $0 |
| Continuing Ops | $-2.7M | $-1.8M | $-58.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-2.7M | $-1.8M | $-58.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-2.7M | $-1.8M | $-58.9M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $19.0K | $25.4K | $8.4M |
| Prepaid Expenses | $6.1K | $1.4K | — |
| Other Current Assets | $12.9K | $24.0K | — |
| Long-Term Assets | $41.3K | $46.9K | $11.3M |
| PP&E (Net) | $302 | — | — |
| Operating Leases | — | — | $59.4K |
| Other LT Assets | $41.0K | — | $11.2M |
| Total Assets | $60.3K | $72.4K | $19.6M |
| Current Liabilities | $3.2M | $3.8M | $5.6M |
| Accounts Payable | $966.7K | $1.2M | $1.2M |
| Other Current Liab | $2.2M | $2.6M | $4.3M |
| Long-Term Liabilities | $19.3K | $58.6K | $147.4K |
| Total Liabilities | $3.2M | $3.9M | $5.7M |
| Shareholders' Equity | $-3.1M | $-3.8M | $13.9M |
| Paid-In Capital | $60.3M | $61.2M | $138.2M |
| Retained Earnings | $-64.7M | $-66.7M | $-125.6M |
| AOCI | $1.3M | $1.3M | $1.3M |
| Treasury Stock | $46.5K | $46.5K | $46.5K |
| Total L&E | $60.3K | $72.4K | $19.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-2.7M | $-1.8M | $-58.9M |
| Non-Cash Adjustments | $1.1M | $331.4K | $57.4M |
| Working Capital Changes | $469.4K | $554.0K | $1.1M |
| Cash from Operations | $-1.1M | $-935.1K | $-405.2K |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $1.1M | $941.9K | $490.8K |
| FX Effect | $-2.5K | $4.3K | $-94.6K |
| Net Change in Cash | $6.0K | $11.0K | $-9.0K |
| Beginning Cash | $4.1K | $10.0K | $21.1K |
| Ending Cash | $10.0K | $21.1K | $12.1K |
Frequently Asked Questions
How does Propanc Biopharma, Inc. make money?
Oncology Therapeutics Development, Preclinical Research & Discovery, and Strategic Licensing Partnerships
What are the main risks for PPCB?
Complete reliance on future financing due to zero revenue stream, potential failure of clinical trials leading to asset impairment, high volatility in stock price typical of pre-commercial biotechs, and regulatory approval uncertainties for novel mechanisms of action.
What is PPCB's competitive advantage?
Access to proprietary technology platforms for drug discovery, a highly experienced management team in the biotech sector, and strategic collaborations that de-risk development programs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.